2020 Update on CDK4/6 Inhibitors in BC: FDA-Approved Practice Changing Palbociclib, Ribociclib & Abemaciclib - What Are the Differences in Dosing, ORR & AE?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 Update on CDK4/6 Inhibitors in BC: FDA-Approved Practice Changing Palbociclib, Ribociclib & Abemaciclib - What Are the Differences in Dosing, ORR & AE?

By PeerView Oncology FEATURING Joyce O'Shaughnessy, Sara Tolaney

1,577 views

October 29, 2020

In this activity, breast cancer experts Joyce O’Shaughnessy, MD, and Sara M. Tolaney, MD, MPH, ...
read more ↘ discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions.
↖ read less

2 Comments